Literature DB >> 16648193

Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy.

Paola Belluardo1, Alessandro Cataliotti, Lorena Bonaiuto, Eliana Giuffrè, Egle Maugeri, Paola Noto, Giovanna Orlando, Giuseppa Raspa, Brigida Piazza, Luciano Babuin, Horng H Chen, Fernando L Martin, Paul M McKie, Denise M Heublein, John C Burnett, Lorenzo S Malatino.   

Abstract

We evaluated relationships among two circulating molecular forms of brain natriuretic peptide (BNP32 and NT-proBNP), severity of hypertension (HTN), and cardiac hypertrophy in subjects with mild, moderate, and severe HTN. We prospectively studied 78 patients (43 males; mean age 51.4 +/- 11 yr) with essential HTN and 28 age- and sex-matched controls. BNP32 and NT-proBNP were measured by radioimmunoassay. In grade 1 HTN, BNP32 was not elevated and NT-proBNP was reduced (P = 0.030) compared with controls. However, log-transformed values of BNP32 and NT-proBNP were both increased with severity of HTN from grade 1 to 3 (P <0.0001 and P = 0.003, respectively). By multivariate analysis, log BNP32 was independently predicted by age (beta = 0.210, P = 0.026) and HTN grade (beta = 0.274, P = 0.004), whereas log NT-proBNP was independently predicted by sex (beta = 0.235, P = 0.012) and HTN grade (beta = 0.218, P = 0.0023). Two forms of BNP were measured in normal subjects and patients with essential HTN. In grade 1 HTN, BNP32 was unchanged and NT-proBNP was significantly reduced compared with controls. As severity increased in humans with grade 1 to 3 HTN, both BNP32 and NT-proBNP levels were increased while not being affected by the presence of left ventricular hypertrophy. The lack of activation of BNP32 together with the reduction of NT-proBNP in grade 1 HTN may represent an impaired response of the BNP system in the early phase of HTN. The later activation of both forms of BNP may be a late compensatory effect, because it correlates with severity of HTN rather than cardiac hypertrophy/remodeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648193     DOI: 10.1152/ajpheart.00107.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  24 in total

1.  Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension.

Authors:  Alessandro Cataliotti; Lisa C Costello-Boerrigter; Horng H Chen; Stephen C Textor; John C Burnett
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

2.  B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension.

Authors:  Sara J Holditch; Claire A Schreiber; Ryan Nini; Jason M Tonne; Kah-Whye Peng; Aron Geurts; Howard J Jacob; John C Burnett; Alessandro Cataliotti; Yasuhiro Ikeda
Journal:  Hypertension       Date:  2015-05-11       Impact factor: 10.190

Review 3.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

4.  Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP.

Authors:  Fima Macheret; Denise Heublein; Lisa C Costello-Boerrigter; Guido Boerrigter; Paul McKie; Diego Bellavia; Sarah Mangiafico; Yasuhiro Ikeda; Kent Bailey; Christopher G Scott; Sharon Sandberg; Horng H Chen; Lorenzo Malatino; Margaret M Redfield; Richard Rodeheffer; John Burnett; Alessandro Cataliotti
Journal:  J Am Coll Cardiol       Date:  2012-10-16       Impact factor: 24.094

5.  Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction.

Authors:  Fima Macheret; Guido Boerrigter; Paul McKie; Lisa Costello-Boerrigter; Brian Lahr; Denise Heublein; Sharon Sandberg; Yasuhiro Ikeda; Alessandro Cataliotti; Kent Bailey; Richard Rodeheffer; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2011-03-22       Impact factor: 24.094

6.  Association of brain-type natriuretic protein and cardiac troponin I with incipient cardiovascular disease in chimpanzees (Pan troglodytes).

Authors:  John J Ely; Tony Zavaskis; Michael L Lammey; Meg M Sleeper; D Rick Lee
Journal:  Comp Med       Date:  2011-04       Impact factor: 0.982

Review 7.  Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon.

Authors:  John C Burnett
Journal:  J Cardiol       Date:  2006-11       Impact factor: 3.159

8.  Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats.

Authors:  Alessandro Cataliotti; Jason M Tonne; Diego Bellavia; Fernando L Martin; Elise A Oehler; Gerald E Harders; Jarryd M Campbell; Kaw-Whye Peng; Stephen J Russell; Lorenzo S Malatino; John C Burnett; Yasuhiro Ikeda
Journal:  Circulation       Date:  2011-03-14       Impact factor: 29.690

9.  Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension.

Authors:  Alessandro Cataliotti; Horng H Chen; John A Schirger; Fernando L Martin; Guido Boerrigter; Lisa C Costello-Boerrigter; Kenneth D James; Karen Polowy; Mark A Miller; Navdeep B Malkar; Kent R Bailey; John C Burnett
Journal:  Circulation       Date:  2008-10-06       Impact factor: 29.690

Review 10.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics.

Authors:  Sarah Mangiafico; Lisa C Costello-Boerrigter; Ingrid A Andersen; Alessandro Cataliotti; John C Burnett
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.